biOasis Technologies Inc Share Price Toronto S.E.
Equities
BTI
CA09064N1033
Biotechnology & Medical Research
Sales 2021 | 4.08M 2.99M 234M | Sales 2022 | 37.72K 27.68K 2.17M | Capitalization | 19.32M 14.18M 1.11B |
---|---|---|---|---|---|
Net income 2021 | - 0 0 | Net income 2022 | -2M -1.47M -115M | EV / Sales 2021 | 5.7 x |
Net cash position 2021 | 2.62M 1.92M 151M | Net Debt 2022 | 171K 125K 9.83M | EV / Sales 2022 | 517 x |
P/E ratio 2021 |
35.1
x | P/E ratio 2022 |
-6.46
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 97.95% |
Managers | Title | Age | Since |
---|---|---|---|
Deborah Rathjen
CEO | Chief Executive Officer | - | 20/09/17 |
Dave Jenkins
DFI | Director of Finance/CFO | - | 30/06/21 |
Mei Mei Tian
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/11 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Hemeon
BRD | Director/Board Member | 59 | - |
David Wurzer
BRD | Director/Board Member | 65 | 26/07/18 |
Deborah Rathjen
CEO | Chief Executive Officer | - | 20/09/17 |
1st Jan change | Capi. | |
---|---|---|
+16.35% | 44.87B | |
-10.63% | 37.8B | |
+40.49% | 37.61B | |
+28.74% | 31.32B | |
-8.44% | 27.4B | |
+12.25% | 26.32B | |
+41.46% | 14.07B | |
+31.95% | 12.5B | |
-7.17% | 11.23B |